GSK's ViiV Healthcare to Present New HIV Treatment and Prevention Data at AIDS 2026

Data will cover daily oral treatments, long-acting injectables and HIV prevention

GSK plc announced that ViiV Healthcare, its global specialist HIV company majority owned by GSK, will present new clinical and real-world data at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil.

The conference is scheduled to take place from July 26 to 31, 2026.

The data will focus on ViiV Healthcare's portfolio of integrase strand transfer inhibitors (INSTIs), including long-acting HIV treatments and prevention options. The company will also share updates from ongoing clinical programmes and real-world studies.

VOGUE Study to Compare Two HIV Treatment Approaches

One of the key data presentations will come from the Phase IIIb VOGUE study.

The study is evaluating the two-drug regimen dolutegravir/lamivudine (DTG/3TC) against the three-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in adults living with HIV who have not previously received HIV treatment.

Additional VOGUE data will provide information about the demographics of people enrolled in the study.

The data will also include information about adults with high viral loads, providing further insight into the use of DTG/3TC in different patient populations.

Pooled Analysis to Look at Viraemic Events

ViiV Healthcare will also present a pooled analysis from clinical trials comparing DTG/3TC with three-drug HIV treatment regimens.

The analysis will focus on on-study viraemic events and clinical outcomes.

These findings are expected to add to the available evidence around the use of two-drug treatment approaches for people living with HIV.

New Data on Long-Acting HIV Treatment

Long-acting injectable HIV treatment will be another major focus of the company's presentations at AIDS 2026.

The data will include updates on cabotegravir plus rilpivirine long acting (CAB+RPV LA), which combines cabotegravir, an integrase strand transfer inhibitor developed by ViiV Healthcare, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor developed by Johnson & Johnson.

Several studies will provide information about the use of this long-acting treatment in different populations and healthcare settings.

LATA Study to Report Week 96 Results

Late-breaking Week 96 results from the LATA study will be presented at the conference.

The study, led by University College London, is evaluating the effectiveness, safety and acceptability of CAB+RPV LA in virologically suppressed adolescents living with HIV across sub-Saharan Africa.

The study compares the injectable treatment with daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir.

The findings will provide additional information about long-acting HIV treatment among adolescents in the region.

OPERA Study Provides Real-World Data

New findings from the OPERA study will also be presented.

The US-based real-world cohort compares the virologic effectiveness of injectable CAB+RPV LA with daily oral BIC/FTC/TAF in adults living with HIV who are already virologically suppressed.

The data will provide insight into how the injectable treatment performs in routine clinical practice compared with a commonly used daily oral regimen.

IMPALA Study Looks at Patients With Previous Adherence Challenges

Week 96 results from the IMPALA study will provide additional information about the use of CAB+RPV LA among adults living with HIV in sub-Saharan Africa.

The study is led by the London School of Hygiene and Tropical Medicine and focuses on people who have experienced adherence challenges in the past.

The findings will examine treatment outcomes over time and provide more information about the role long-acting treatment may play for people who have found it difficult to maintain daily oral treatment routines.

Survey Examines Conversations About Long-Acting HIV Treatment

Data from the Ask Us Europe community co-produced survey will also be presented.

The survey, led by an academic team in London, looks at whether people living with HIV across Europe are having meaningful and equitable conversations with their healthcare providers about long-acting HIV treatment options.

The findings are expected to provide insight into how patients and healthcare professionals discuss different treatment choices and whether people have equal access to information about long-acting options.

HIV Prevention Data to Include CAB LA for PrEP

ViiV Healthcare will also present new data on long-acting cabotegravir (CAB LA) for HIV pre-exposure prophylaxis, commonly known as PrEP.

The presentations will include findings from studies looking at how long-acting injectable prevention options are used, accepted and delivered in real-world settings.

CLARITY Study Compares CAB LA With Lenacapavir

Six-month data from the Phase I CLARITY study will examine participant experiences with CAB LA and lenacapavir injections after a single dose.

The study will assess how participants view and accept the two long-acting injectable approaches.

Late-breaking participant-reported outcomes will also be presented. These findings may provide additional information for healthcare professionals and people considering long-acting injectable options for HIV prevention.

Real-World PrEP Studies to Provide Additional Information

The CAPTIVATE study will present data on the real-world use, acceptability and delivery of CAB LA for PrEP in routine US clinical practice.

Updated findings from PrEPFACTS will also examine real-world use and adherence patterns for CAB LA for PrEP in the United States.

The PrEPFACTS analysis uses healthcare administrative claims data to provide information about how the prevention treatment is being used outside clinical trials.

New Three-Times-a-Year PrEP Formulation Under Evaluation

ViiV Healthcare will also share baseline data from the Phase IIb registrational EXTEND 4M trial.

The study is evaluating a new formulation of long-acting cabotegravir that could potentially be administered three times a year for HIV PrEP.

The programme builds on existing evidence for CAB LA for PrEP, which is currently administered six times a year.

EXTEND 4M will assess the pharmacokinetics, safety and tolerability of the new formulation.

The baseline data will describe the population enrolled in the study and provide an early look at the clinical programme evaluating the new dosing approach.

Cabenuva Provides a Long-Acting HIV Treatment Option

Cabenuva is a complete HIV-1 treatment regimen for eligible adults and adolescents aged 12 years and older who weigh at least 35 kg.

The treatment is intended for people who are already virologically suppressed on a stable antiretroviral regimen, have no history of treatment failure and have no known or suspected resistance to cabotegravir or rilpivirine.

The regimen combines cabotegravir with rilpivirine.

Cabotegravir belongs to the INSTI class, while rilpivirine is an NNRTI. Together, the medicines work through different mechanisms to prevent HIV from multiplying.

How Integrase Inhibitors Work

Integrase strand transfer inhibitors, or INSTIs, work by blocking an important step in the HIV replication process.

HIV needs to integrate its viral DNA into the genetic material of human immune cells to continue its replication cycle. INSTIs interfere with this process, helping prevent the virus from multiplying.

Rilpivirine works differently. It blocks an enzyme called reverse transcriptase, which HIV needs to replicate.

Dovato Offers a Two-Drug HIV Treatment

ViiV Healthcare's Dovato is another treatment highlighted in the company's HIV portfolio.

Dovato is indicated for the treatment of HIV-1 infection in eligible adults and adolescents aged 12 years and older who meet the relevant weight requirements and have no known or suspected resistance to the integrase inhibitor class or lamivudine.

The treatment combines dolutegravir and lamivudine as a two-drug regimen.

Apretude Used for HIV Prevention

Apretude is a long-acting injectable medicine used for HIV-1 pre-exposure prophylaxis.

It is intended for eligible adults and adolescents who are at high risk of acquiring HIV and should be used alongside safer sex practices, including condom use.

Apretude contains cabotegravir, the same active substance used in the long-acting treatment regimen Cabenuva.

ViiV Healthcare Focuses on HIV Treatment and Prevention

ViiV Healthcare was established in 2009 and currently has GSK and Shionogi as shareholders.

The company focuses specifically on HIV treatment and prevention, with the aim of developing medicines and healthcare solutions for people living with HIV and those who may benefit from HIV prevention.

The data being presented at AIDS 2026 cover multiple areas of the company's portfolio, including daily oral treatment, long-acting injectable therapies, HIV prevention and new dosing approaches under clinical development.

GSK is a global biopharmaceutical company focused on combining science, technology and talent to develop medicines and vaccines and address major health challenges.